Astellas to sale off the Oncology line by 2015

Quote
Oncology got a whopping 40% increase in history for its FY 2015 objective. Same is true for other divisions. Good way to drive sales people out before the sell off, if that's what the plan is. Bad decision...unless you're getting out of the business in the U.S....at least.
 






I have been seeing Doctors, mostly Oncologists in past few years. All they have been asking me is, if Xtantdi going to work after Zytiga? When I asked why and the fact they should use Xtandi first, their rep,y is: It doesn't matter anymore since some insurance companies are signaling that from end of this year, beginning of next year, Zytiga should be used first as it is going to be generic, from December of this year and will be substantially cheaper than Xtandi.
 


















just saw the news that NICE in UK will not provide coverage for Enzalutamide in pre-chemo setting. I could see their rational from financial and impact in Health system budget as Enzalutamide does not have any trial justifying their use in Pre-Chemo based on Overall Survival (OS) advantage.
In order for NICE or other agencies considering coverage for Enzalutamide in Pre-Chemo setting, Enzalutamide has to show far better OS if and when used in Pre-Chemo setting vs when it is used post Chemo.
NICE and other agencies would like patient receive available generic therapies first, Taxotere, before start of brand therapy, especially when there is NO significant in OS when branded therapy is used pre vs post available generic therapy.
Soon Abiraterone becomes generic too and it. Will also impact the use of Enzalutamide in similar fashion.
 












I see the resignation of the Global Medical Lead for Xtandi. Too bad, no one else is left who has a slight clue about Oncology never the less Prostate Cancer. I guess similar to her former colleagues she saw the writing on the wall. It is very clear that focus will be in Vaccines and vision care NOT Oncology.
 






Top Bottom
Back
Quote